Gilead Sciences, Inc. (GILD) Yield on Cost (YOC): 2.63%
The yield on cost (YOC) for Gilead Sciences, Inc. (GILD) is 2.63%.
GILD Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
2.63%
Yield on Cost for GILD
GILD now pays $3.19 per share a year. Measured against the price it actually traded at back then, a long-term holder is earning:
| If you bought | Price then | Yield on cost today |
|---|---|---|
| 10 years ago(2016-06-08) | $87.42 | 3.65% |
| 5 years ago(2021-06-04) | $67.43 | 4.73% |
| 3 years ago(2023-06-06) | $76.20 | 4.19% |
| 1 year ago(2025-06-10) | $110.09 | 2.90% |
| Buying today(at $121.48) | $121.48 | 2.63% |
If you buy today and the dividend keeps growing
Projection: starting from today's 2.63% yield, assuming the dividend keeps compounding at its historical 3.0% rate. Boards set dividends each year, so actual figures will differ.
Today
2.63%
In 3 years
2.92%
In 5 years
3.14%
In 10 years
3.75%
Yield on Cost Calculator
Try your own purchase price, dividend and growth rate for Gilead Sciences, Inc. (GILD).
Starting Yield
2.63%
Ending YOC
4.12%
Year 15 Dividend
$5.00
Cum. Dividends Recd.
$61.31
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $3.19 | — | 2.63% | $0.00 |
| Year 1 | $3.29 | +3.04% | 2.71% | $3.29 |
| Year 2 | $3.39 | +3.04% | 2.79% | $6.67 |
| Year 3 | $3.49 | +3.04% | 2.87% | $10.16 |
| Year 4 | $3.60 | +3.04% | 2.96% | $13.76 |
| Year 5 | $3.71 | +3.04% | 3.05% | $17.46 |
| Year 6 | $3.82 | +3.04% | 3.14% | $21.28 |
| Year 7 | $3.93 | +3.04% | 3.24% | $25.22 |
| Year 8 | $4.05 | +3.04% | 3.34% | $29.27 |
| Year 9 | $4.18 | +3.04% | 3.44% | $33.45 |
| Year 10 | $4.30 | +3.04% | 3.54% | $37.75 |
| Year 11 | $4.43 | +3.04% | 3.65% | $42.19 |
| Year 12 | $4.57 | +3.04% | 3.76% | $46.76 |
| Year 13 | $4.71 | +3.04% | 3.88% | $51.46 |
| Year 14 | $4.85 | +3.04% | 3.99% | $56.31 |
| Year 15 | $5.00 | +3.04% | 4.12% | $61.31 |
Gilead Sciences, Inc. Yield on Cost (YOC) Formula & Definition
Yield on cost is the dividend yield measured against your original purchase price, not today's price. As a company raises its dividend, the yield on what you actually paid keeps rising even when the market yield holds steady.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gilead Sciences, Inc. Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for Gilead Sciences, Inc. (GILD)?
- The yield on cost (YOC) for GILD stock is 2.63%.
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day